Every material Form 8-K Health Catalyst, Inc. has filed with the SEC since September 08, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Health Catalyst reported third-quarter 2026 revenue of $56.3 million, down 26% from $76.3 million a year earlier, and Adjusted EBITDA of $779 thousand, versus $12.0 million. GAAP net income was $40.5 million, compared with a $22.2 million loss, largely because of a $65.9 million gain on the sale of its Vitalware business, which closed on July 31, 2026. The company reaffirmed its full-year 2026 guidance of $246 million to $249 million in revenue and $18 million to $18.5 million in Adjusted EBITDA.
Q3 2026 revenue was $56.3 million, down from $76.3 million; gross margin was 31%, down from 39%.
GAAP net income was $40.5 million, or $0.53 per diluted share, versus a net loss of $22.2 million; the result includes a $65.9 million gain on the Vitalware sale.
Adjusted EBITDA was $779 thousand, down from $12.0 million a year earlier.
Full-year 2026 guidance was reaffirmed: total revenue of $246 million to $249 million and Adjusted EBITDA of $18 million to $18.5 million.
Health Catalyst appointed Tami Reller as a Class III director, effective October 1, 2026, expanding the board from six to seven members. She will also chair the Audit Committee and join the Compensation Committee. The company's press release also states that Simeon Kohl was named Chief Executive Officer and President, effective September 14, 2026.
Tami Reller appointed to the board effective October 1, 2026, filling a newly created seat
Board expands from six to seven directors, effective October 1, 2026
Reller replaces Justin Spencer as Audit Committee chair; Spencer remains on the committee
Press release states Simeon Kohl was named CEO and President effective September 14, 2026
Health Catalyst's Board appointed Simeon Kohl as Chief Executive Officer, President, and a Class III director, effective September 14, 2026. Ben Albert resigned as CEO, President, and director, effective September 13, 2026, and will serve as Chief Business Officer; the filing says his resignation is not the result of any disagreement with the Company.
Kohl's salary is $600,000, with an annual bonus target of 100% of base salary.
The Board plans to grant Kohl 2,747,385 restricted stock units, with 915,975 vesting on September 4, 2027.
Albert's salary as Chief Business Officer is $415,000, effective September 14, 2026.
The Board adopted the 2026 Employment Inducement Incentive Plan, reserving 2,747,385 shares without stockholder approval under Nasdaq Rule 5635(c)(4).
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Health Catalyst, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →